News | Cardiac Diagnostics | August 07, 2015

Boehringer Ingelheim to Sponsor ACC-Led Diabetes Collaborative Registry

Pharmaceutical company becomes latest participant in national data repository for coordinated care of diabetes patients

ACC, Boehringer Ingelheim, Diabetes Collaborative Registry, American College of Cardiology

August 7, 2015 — The American College of Cardiology (ACC) has announced that Boehringer Ingelheim is the newest industry sponsor of The Diabetes Collaborative Registry. The registry is an interdisciplinary effort led by the college in partnership with the American Diabetes Association, the American College of Physicians, the American Association of Clinical Endocrinologists and the Joslin Diabetes Center.

“Heart disease is the leading cause of death for people with diabetes,” said American College of Cardiology President Kim Allan Williams, M.D., FACC. “Their unique needs call for cross-specialty care that will be made possible through the Diabetes Collaborative Registry, and we thank Boehringer Ingelheim for joining the effort to support the continued, accelerated growth of this registry.”

Since the official launch of the Diabetes Collaborative Registry just one year ago, interest and participation in the program has exceeded expectations. To date, more than 100 cross-specialty practice entities have enrolled in the registry, expanding an already robust national footprint spanning nearly 500 practice locations with 1,300 providers across 28 states.

Additional support will allow the registry to scale up and increase its impact, including outreach to and enrollment of a larger installation base of practices and health systems, enhanced quality improvement performance reports delivered to participants, and more data collection to drive actionable insights and decision-making to improve the quality of care delivered to the right patients at the right time.

The Diabetes Collaborative Registry aspires to create the largest single repository of real-world clinical information on diabetes and cardiometabolic care in the world to improve the quality of life for all people living with these conditions.

Patients with diabetes often receive treatments across multiple medical specialties for a multitude of related conditions. The Diabetes Collaborative Registry will allow for a longitudinal study of diabetes across all stages of the disease—including presentation, progression, management and outcomes—even as patients receive treatment from multidisciplinary care teams. It will also incorporate the growing number of patients with diabetes in the ACC’s PINNACLE Registry, which is the nation’s largest ambulatory cardiovascular registry.

Participation in the registry is expected to yield long-term benefits for practices, providers and patients, as physicians can track adherence and performance against evidence-based national metrics and benchmarks at the provider, practice and site level through regular reports received; can identify potential areas to target for quality improvement opportunities; may meet requirements for federal incentive reporting programs, such as the Centers for Medicare and Medicaid Services’ Physician Quality Reporting System and Electronic Health Care Record Incentive Program; and will, ultimately, transform the quality of care provided to patients across the continuum of ambulatory primary and specialty care.

Researchers will have the opportunity to gather insights from this repository of diabetes care data from various providers in outpatient settings, and patients will benefit from their physicians’ increased access to a central repository of diabetes data based on the latest science and research that can be used to tailor their care. The registry maintains an aggressive outcomes research agenda and is anticipated to complete a number of research abstracts and manuscripts by the conclusion of this year.

For more information: www.acc.org

Related Content

Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init